Skip to content

Semibranch Registry - Retrospective

Outcome of the Semibranch in Pararenal and Thoracoabdominal Aortic Pathologies. A Retrospective, Multicentre Registry

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06374355
Enrollment
100
Registered
2024-04-18
Start date
2024-07-02
Completion date
2030-10-31
Last updated
2024-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aortic Aneurysm, Endovascular Aortic Repair, Stent-Graft Endoleak

Brief summary

The goal of this registry is to evaluate the semibranch in branched endovascular arotic repair, which is a new tool in endovascular branched aortic repair.

Detailed description

The main question it aims to answer are: * Patency of the semibranch * Feasibility of the technique regarding cannulation and stentgrafting

Interventions

bEVAR with a custom made abdominal aortic multibranch, which incorporates the semibranch design

Sponsors

University Hospital Muenster
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient has been treated with the semibranch stentgraft * Patient is over 18 years old

Design outcomes

Primary

MeasureTime frameDescription
Freedom from target vessel instability30 days after interventionPrimary patency and freedom from stenosis of the semibranch
Mortality30 days after interventionOverall mortality rate during 30 days after intervention
Technical success12 hours after interventioncannulation and stentgrafting ot the semibranches

Secondary

MeasureTime frameDescription
MorbidityDuring follow up period (up to 3 years)Access site, bowel ischemia, kidney failure, paraplegia
Branch patencyDuring follow up period (up to 3 years)Primary patency of all branches
Freedom of Endoleak type I and IIIDuring follow up period (up to 3 years)Abscence of endoleaks arising from the semibranch
Long term mortalityDuring follow up period (up to 3 years)Overall mortality up to 3 years

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026